In the big changes in the industry, how do pharmaceutical companies deal with the single problem of product structure?

"Pharmaceutical Network Industry Dynamics" recently, Sapp Ace issued a notice that its core product lysine eye drops (commodity name: Shapps) quality and efficacy consistency evaluation work can not be completed in accordance with the requirements of the National Drug Administration within three years.
this case, the drug approval may be cancelled or not re-registered after expiration, which will also result in the product being unable to continue production and sale.
reported that the news, Sapp Ace's share price fell in response.
pharmaceutical companies how to deal with the product structure of a single problem (picture source: pharmaceutical network) product structure of a single, pharmaceutical companies fatal short board industry analysis that if this situation is true, Sapp Ais will face a huge development crisis.
fact, the current difficulties facing Sapp Ace are not just the core products may not be able to pass a consistent evaluation, from a deeper point of view, the product structure is a single is its really deadly short board.
At present, the pharmaceutical industry has entered a high-quality development, industrial transformation of the innovation era, in the past a variety of sales can live well development logic is no longer appropriate, more and more institutions of a single pharmaceutical companies are encountering a development crisis.
this is evident from the declining performance of Sapp Ace in recent years.
data show that Sapp Ace's pyrethrin eye drops are its main products, once occupied 80% of the domestic market share of cataract eye drops, in advertising this product even sold 750 million a year.
But in the after-effects of the "God Medicine" storm, sales of Sharp's eye drops fell 51.51 percent year-on-year in 2018, while revenue fell to 53.5 percent, and revenue from the company fell 52.58 percent year-on-year to 325 million yuan.
revenue for the first three quarters of 2020 was RMB240 million, down 40.61 percent year-on-year, and net profit loss was RMB28,056.5 million, down 171.65 percent year-on-year.
Pharmaceutical companies actively adjust their strategies, innovation into the general trend of the trend in fact, the industry, such as Sapp Ace, relying on a single product to complete the company's main source of income is not a minority of pharmaceutical companies, and therefore "big injury" pharmaceutical companies have a precedent.
As in the second round of drug collection at the beginning of this year, Acapo glycogen research drug with 0.18 yuan / piece of the bid, so that A capo sugar generics leading enterprises lost 2 billion levels of the market.
From the above overall point of view, in the current pharmaceutical industry into high-quality development, industry accelerated transformation of the background, research and development capacity is weak, mainly by sales to drive the performance of a single product enterprises will face the industry upgrade brought about by the huge competition.
even large varieties of billions of sales, such as ida/lysine eye drops, are hard to ignore, which is the pain of high-quality development of the industry.
in this industry change, how should pharmaceutical companies deal with the single product structure problem? Industry insiders believe that by continuously improving and upgrading the level of research and development, optimize the research and development pattern and level, focus on promoting the progress of key research and development projects, existing product upgrading projects, speed up the progress of new product launches and other measures, or can reduce the risk of relying solely on the core products brought about by the more concentrated.
Russi Pharmaceuticals, which started out as a generic drug and occupies a leading position in the industry, has been stepping up research and development of innovative drugs since 2018, with the 2018 annual report showing that the company has invested a total of 2.670 billion yuan in research and development in 2018, accounting for 15.33 percent of its sales revenue for the year;
Against the background of increasing innovation investment, Hengrui Pharmaceuticals is systematically building heavy-weight varieties such as Apatini, Karelli Pearl Monoanti and Fluorine Pali to amplify the clinical and commercial value of each product.
addition, in the key therapeutic areas, with its product pipeline, clinical progress, adaptive layout, joint drug treatment programs and other advantages, but also continue to deepen the expansion of innovative drug mohes.
conclusion, China's pharmaceutical market pattern is changing dramatically.
promoted by the comprehensive industrial policy, the future production enterprises will form polarization, both innovative enterprises and processing enterprises.
, under the trend of innovation, a number of production enterprises with research and development strength precipitation can have more development opportunities.
refore, pharmaceutical companies must continue to promote the reserve of new products through innovation and other means, expand the breadth and depth of the product market, and actively improve the situation of relying solely on a single product, improve the enterprise's ability to resist risks.